Additional file 1: of Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma

Figure S1. Purity of infused allogenic Vγ9Vδ2 T cells of all 8 treatment courses is > 85%. According to flow cytometry data, rest non Vδ2 T cells including Vδ1 T cells, NK cells, B cells, NKT cells, CD8+T cells, CD4+T cells, CD4+CD8+T cells, and CD4-CD8-T cells. Figure S2. Molecular phenotypes of allogenic Vγ9Vδ2 T cells cultured using our developed specific culture formula, showing high expression of killing related molecules (like NKG2D, IFN-γ, TNF-α, CD107a) and low expression of inhibitory molecules like PD-1. (PPTX 255 kb)